Telix Pharmaceuticals (ASX: TLX) has completed the CUPID study, a Phase I trial on its investigational drug TLX592 for prostate cancer patients

Related Keywords

Davidn Cade , , Telix Pharmaceuticals , Sonic Healthcare ,